ABOUT US
The foundation of IMU is built on the belief that deep systems level immunophenotyping at a population level, powered by the latest advancements in AI and Machine Learning, will lead to a totally new understanding of the immune system and help develop the next-generation precision medicines. IMU is fulfilling this vision with its proprietary discovery engine, and building a comprehensive Immune Atlas that covers the spectrum of health and disease, to advance precision medicine.
The technology is the result of ten years of research from King’s College London and was initially applied during the COVID-19 pandemic. Co-founders Dr. Adam Laing and Dr. Tom Hayday demonstrated the effectiveness of the platform in understanding the human immune response to the virus. The success of this project not only showcased the technology's potential but also underscored its wide applicability in multiple healthcare fields, with the potential to transform how we approach health and disease. IMU has built an amazing team of healthcare experts, immunologists, technologists and researchers to make this bold mission a reality.
At IMU, we strongly believe that in the future, no medical decision will be made without an understanding of a patient's immune system.
Our investors
.svg)
